Profound Medical Corp faced a challenging session, with its stock dropping significantly.
Shares of Profound Medical Corp (PRN.TO) fell yesterday, closing down 4.68% at CA$11.21. This decline highlights ongoing concerns surrounding the company's recent performance and market sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Profound Medical Corp
PRN.TO
PRN.TO
Profound Medical Corp
WealthAwesomeMarket cap
$427.33M
52W high
$12.40
52W low
$5.23
1W change
+9.47%
Beta
0.53
Analyst Price Targets
Based on analyst covering PRN
Wall Street analysts forecast PRN stock price to rise 123.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.03
+123.3% Upside
Current Price
C$11.21
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRN's historical volatility
30-Day Vol
55.8%
Annualized
90-Day Vol
54.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.90 | C$9.81 – C$14.42 |
| 60 trading days | C$12.63 | C$9.62 – C$16.58 |
| 90 trading days | C$13.40 | C$9.60 – C$18.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Profound Medical's upcoming financial results and trial outcomes as they could significantly impact stock performance.
4.68% Decline in Stock Value
Profound Medical's market cap now stands at CA$427.33 million, reflecting investor caution amidst recent trial results.
Bull case
If the upcoming trials show positive results, or if the company can effectively demonstrate the efficacy of its TULSA-PRO® system, we might see a rebound in stock value.
Bear case
On the other hand, if clinical trials continue to face setbacks, like the recent CAPTAIN trial, investor confidence may wane further, leading to additional declines.
Market Reaction to Recent Trials
Advertisement
Profound Medical's stock decline can be attributed to disappointing results from the CAPTAIN trial, which did not meet its primary endpoint. This news has raised concerns among investors regarding the company's future prospects and its ability to deliver on its promises in the competitive healthcare market.
Upcoming Financial Results
Investors are now looking ahead to the scheduled release of Profound Medical's Q2 2026 financial results on August 6, 2026. This report will be crucial for assessing the company's financial health and could significantly influence stock performance. For more details, visit our Profound Medical stock page.
Investor Sentiment and Future Outlook
The recent drop in stock price reflects a broader sentiment of caution among investors. As Profound Medical navigates through its clinical trials and prepares for upcoming results, the market will be watching closely for signs of recovery or further decline. For ongoing updates, check our Profound Medical stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
